PM360 July 13, 2023 Read the full article>> Reasons for Discontinuation (RfD) Analytics Report An estimated 50% of patients with a prescription for a chronic condition stop taking it within the first year, leading to worse outcomes and nearly $250 billion lost revenue annually for the pharmaceutical industry. To combat this, OM1 launched its Reasons for Discontinuation[…]
June 26, 2023 BOSTON–(BUSINESS WIRE)–OM1, a leading real-world data and technology company with a focus on chronic conditions, today announced the launch of OM1 Aspen, its novel, automated study platform for evidence generation. OM1 Aspen is a comprehensive offering that is distinguished by the company’s proprietary data sourcing, processing, and enrichment technologies – including electronic medical[…]
June 22, 2023 newswise Read the full release >> Newswise — Rosemont, Ill. (June 22, 2023) – The American Academy of Dermatology, with critical support from Boehringer Ingelheim, and powered by OM1’s data aggregation system and its PhenOM™ artificial intelligence (AI) platform, is launching an innovative breakthrough project to develop educational resources to improve the evaluation, diagnosis,[…]
Patti Peeples June 22, 2023 The Evidence Base Watch the full interview >>
Healio June 09, 2023 Robert Herpen Read the full article>> Key takeaways: A machine learning model processed data from more than 32,000 records, 96,000 encounters of those with MDD. Application of the model created an exponential amount of PHQ-9 scores and patient records. MIAMI BEACH, Fla. — A novel machine learning model accurately estimated scores[…]
